Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
By D. Vigil, J. Cherfils, K. Rossman, C. Der. Nature Reviews. Cancer, 2010
800 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/3dfc476aa0dc7484222e3cabc4de97217c6ad66b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Brent R. Stockwell
- Scott J. Dixon
- Eric S. Lander
- W. Yang
- Gad Getz
- Matthew Meyerson
- K. Rossman
- Alexey I. Nesvizhskii
Citations in the corpus
- RAS isoforms and mutations in cancer at a glance (2016, background): “distinct protein signaling cascade (Vigil et al., 2010).”
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, background): “OFF molecular switch, cycling between an active guanosine triphosphate (GTP)-bound and inactive guanosine diphosphate (GDP)-bound state (Vigil et al. 2010a).”
- Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma (2020, background): “SOS1 is a guanine exchange factor (GEF) that activates KRAS (Vigil et al., 2010), and inhibition of SOS1 and KRAS is an emerging therapeutic strategy for KRAS mutant cancers (Hillig et al.”
- Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy (2012, background): “Thus, the GEFs and GAPs balance underlie and facilitate Ras activation and inactivation, respectively [16].”
- Ferroptosis: an iron-dependent form of nonapoptotic cell death. (2012, background): “The RAS family of small GTPases (HRAS, NRAS, and KRAS) are mutated in 30% of all cancers (Vigil et al., 2010).”
- A Landscape of Driver Mutations in Melanoma (2012, background): “Given the role of NF1 as a negative regulator of RAS signaling (Vigil et al., 2010), these results suggest that NF1 inactivation may confer 258 Cell 150, 251–263, July 20, 2012 ª2012 Elsevier Inc. aberrant mitogen-activated protein kinase (MAPK) pathway activation in these BRAF/NRAS wild-type…”
- Drugging the ‘undruggable’ cancer targets (2017, positive): “The RAS superfamily actually consists of about 150 related proteins, such as RAC and RHO, which also regulate multiple signal transduction pathways 9 .”